This page shows a list of our current and old partners.
In March 2013, we entered a collaboration with Cargill to jointly develop and commercialize fermentation-derived steviol glycosides. Cargill will be responsible for commercialization and has agreed to make a CHF 5 million (approximately USD 5.4 million) equity investment in Evolva. Additionally, Evolva stands to receive up to USD 7.5 million in milestone payments and has the right to a 45% participation in the final business. If Evolva decides not to exercise this option it will receive royalty payments from global sales of the co-developed steviol glycoside products; these royalties will scale from mid-single digit to low double-digit percentages as a function of sales volume and other parameters.
Cargill is an international producer and marketer of food, agricultural, financial and industrial products and services. Founded in 1865, the privately held company employs 142,000 people in 65 countries. Cargill helps customers succeed through collaboration and innovation, and is committed to sharing its global knowledge and experience to help meet economic, environmental and social challenges wherever it does business.
In January 2011 Evolva announced a collaboration and joint development agreement with International Flavors & Fragrances Inc. (IFF), one of the world’s leading creators and manufacturers of flavours and fragrances for consumer products. The objective of the collaboration is to implement a commercially viable biosynthetic route for the production of vanillin. In January 2013, Evolva and IFF have entered into pre-production phase to develop and scale-up, via a third party, natural vanillin for commercial application through a cost-effective, natural and sustainable route. The two companies are working to confirm scalability and yield targets through a yeast-based fermentation route during the pre-manufacturing phase.
Under the agreement, IFF is funding research and development projects at Evolva, focused primarily on pathway discovery and yield stages, through the scale-up and manufacturing phases. Evolva has received upfront payments and receives monthly research fees. Furthermore, Evolva will receive royalty on product sales based on both margin and volume.
In February 2014 we announced a collaboration agreement with L’Oréal for the co-development of novel biosynthetic production routes for an undisclosed ingredient with broad applications in the cosmetics industry. Evolva and L’Oréal will apply Evolva’s fermentation technology platform to develop and optimise yeast strains for the sustainable, cost-effective production of this strategically important cosmetics ingredient. This collaboration began in early 2014 and will conclude in late 2016, and includes an option to expand the ingredient focus. L’Oréal will pay Evolva research fees during the project period. Additionally, Evolva is eligible to receive milestone payments based on achieving research objectives.
In January 2013, we moved into a collaboration with Ajinomoto for joint development of novel fermentation production routes for a natural functional ingredient for application in Personal Care. Ajinomoto Co is a world leader in the area of amino acids. The collaboration will run for 3½ years and involve 7 full-time scientists of Evolva.
At the start of 2012, we announced a collaboration with Roquette, covering joint research and development of novel and optimised biosynthetic production routes for an ingredient with important applications in food products. Roquette is a world leader in the area of nutrition and other products based on raw vegetable materials. The collaboration will run for up to 4.5 years and involve c. 7% of Evolva’s R&D headcount.